<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T09:53:53Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:10804931" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:10804931</identifier>
        <datestamp>2024-02-01</datestamp>
        <setSpec>elsevierwt</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article" dtd-version="1.3">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Kidney Int</journal-id>
              <journal-id journal-id-type="iso-abbrev">Kidney Int</journal-id>
              <journal-title-group>
                <journal-title>Kidney International</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0085-2538</issn>
              <issn pub-type="epub">1523-1755</issn>
              <publisher>
                <publisher-name>Elsevier</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC10804931</article-id>
              <article-id pub-id-type="pmcid">PMC10804931</article-id>
              <article-id pub-id-type="pmc-uid">10804931</article-id>
              <article-id pub-id-type="pmid">37914088</article-id>
              <article-id pub-id-type="pii">S0085-2538(23)00760-3</article-id>
              <article-id pub-id-type="doi">10.1016/j.kint.2023.09.032</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Clinical Trial</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>A pragmatic, open-label, randomized controlled trial of Plasma-Lyte-148 versus standard intravenous fluids in children receiving kidney transplants (PLUTO)</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author" id="au1">
                  <name>
                    <surname>Hayes</surname>
                    <given-names>Wesley N.</given-names>
                  </name>
                  <email>wesley.hayes@gosh.nhs.uk</email>
                  <xref rid="aff1" ref-type="aff">1</xref>
                  <xref rid="aff2" ref-type="aff">2</xref>
                  <xref rid="cor1" ref-type="corresp">∗</xref>
                </contrib>
                <contrib contrib-type="author" id="au2">
                  <name>
                    <surname>Laing</surname>
                    <given-names>Emma</given-names>
                  </name>
                  <xref rid="aff3" ref-type="aff">3</xref>
                </contrib>
                <contrib contrib-type="author" id="au3">
                  <name>
                    <surname>Brown</surname>
                    <given-names>Rosemary</given-names>
                  </name>
                  <xref rid="aff3" ref-type="aff">3</xref>
                </contrib>
                <contrib contrib-type="author" id="au4">
                  <name>
                    <surname>Silsby</surname>
                    <given-names>Laura</given-names>
                  </name>
                  <xref rid="aff3" ref-type="aff">3</xref>
                </contrib>
                <contrib contrib-type="author" id="au5">
                  <name>
                    <surname>Smith</surname>
                    <given-names>Laura</given-names>
                  </name>
                  <xref rid="aff3" ref-type="aff">3</xref>
                </contrib>
                <contrib contrib-type="author" id="au6">
                  <name>
                    <surname>Thomas</surname>
                    <given-names>Helen</given-names>
                  </name>
                  <xref rid="aff3" ref-type="aff">3</xref>
                </contrib>
                <contrib contrib-type="author" id="au7">
                  <name>
                    <surname>Kaloyirou</surname>
                    <given-names>Fotini</given-names>
                  </name>
                  <xref rid="aff3" ref-type="aff">3</xref>
                </contrib>
                <contrib contrib-type="author" id="au8">
                  <name>
                    <surname>Sharma</surname>
                    <given-names>Rupa</given-names>
                  </name>
                  <xref rid="aff3" ref-type="aff">3</xref>
                </contrib>
                <contrib contrib-type="author" id="au9">
                  <name>
                    <surname>Griffiths</surname>
                    <given-names>James</given-names>
                  </name>
                  <xref rid="aff3" ref-type="aff">3</xref>
                </contrib>
                <contrib contrib-type="author" id="au10">
                  <name>
                    <surname>Hume-Smith</surname>
                    <given-names>Helen</given-names>
                  </name>
                  <xref rid="aff4" ref-type="aff">4</xref>
                </contrib>
                <contrib contrib-type="author" id="au11">
                  <name>
                    <surname>Marks</surname>
                    <given-names>Stephen D.</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                  <xref rid="aff2" ref-type="aff">2</xref>
                </contrib>
                <contrib contrib-type="author" id="au12">
                  <name>
                    <surname>Kessaris</surname>
                    <given-names>Nicos</given-names>
                  </name>
                  <xref rid="aff5" ref-type="aff">5</xref>
                </contrib>
                <contrib contrib-type="author" id="au13">
                  <name>
                    <surname>Christian</surname>
                    <given-names>Martin</given-names>
                  </name>
                  <xref rid="aff6" ref-type="aff">6</xref>
                </contrib>
                <contrib contrib-type="author" id="au14">
                  <name>
                    <surname>Dudley</surname>
                    <given-names>Jan</given-names>
                  </name>
                  <xref rid="aff7" ref-type="aff">7</xref>
                </contrib>
                <contrib contrib-type="author" id="au15">
                  <name>
                    <surname>Shenoy</surname>
                    <given-names>Mohan</given-names>
                  </name>
                  <xref rid="aff8" ref-type="aff">8</xref>
                </contrib>
                <contrib contrib-type="author" id="au16">
                  <name>
                    <surname>Malina</surname>
                    <given-names>Michal</given-names>
                  </name>
                  <xref rid="aff9" ref-type="aff">9</xref>
                </contrib>
                <contrib contrib-type="author" id="au17">
                  <name>
                    <surname>Muorah</surname>
                    <given-names>Mordi</given-names>
                  </name>
                  <xref rid="aff10" ref-type="aff">10</xref>
                </contrib>
                <contrib contrib-type="author" id="au18">
                  <name>
                    <surname>Ware</surname>
                    <given-names>Nicholas</given-names>
                  </name>
                  <xref rid="aff11" ref-type="aff">11</xref>
                </contrib>
                <contrib contrib-type="author" id="au19">
                  <name>
                    <surname>Yadav</surname>
                    <given-names>Pallavi</given-names>
                  </name>
                  <xref rid="aff12" ref-type="aff">12</xref>
                </contrib>
                <contrib contrib-type="author" id="au20">
                  <name>
                    <surname>Reynolds</surname>
                    <given-names>Ben</given-names>
                  </name>
                  <xref rid="aff13" ref-type="aff">13</xref>
                </contrib>
                <contrib contrib-type="author" id="au21">
                  <name>
                    <surname>Bryant</surname>
                    <given-names>William</given-names>
                  </name>
                  <xref rid="aff14" ref-type="aff">14</xref>
                </contrib>
                <contrib contrib-type="author" id="au22">
                  <name>
                    <surname>Spiridou</surname>
                    <given-names>Anastassia</given-names>
                  </name>
                  <xref rid="aff14" ref-type="aff">14</xref>
                </contrib>
                <contrib contrib-type="author" id="au23">
                  <name>
                    <surname>Wray</surname>
                    <given-names>Jo</given-names>
                  </name>
                  <xref rid="aff15" ref-type="aff">15</xref>
                </contrib>
                <contrib contrib-type="author" id="au24">
                  <name>
                    <surname>Peters</surname>
                    <given-names>Mark J.</given-names>
                  </name>
                  <xref rid="aff2" ref-type="aff">2</xref>
                  <xref rid="aff16" ref-type="aff">16</xref>
                </contrib>
                <aff id="aff1"><label>1</label>Department of Pediatric Nephrology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK</aff>
                <aff id="aff2"><label>2</label>University College London Great Ormond Street Institute of Child Health, London, UK</aff>
                <aff id="aff3"><label>3</label>National Health Service Blood and Transplant Clinical Trials Unit, Cambridge, UK</aff>
                <aff id="aff4"><label>4</label>Department of Anesthetics, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK</aff>
                <aff id="aff5"><label>5</label>Department of Transplant Surgery, Guys and St Thomas NHS Foundation Trust, London, UK</aff>
                <aff id="aff6"><label>6</label>Department of Pediatric Nephrology, Nottingham Children’s Hospital, Nottingham, UK</aff>
                <aff id="aff7"><label>7</label>Department of Pediatric Nephrology, Bristol Children’s Hospital, Bristol, UK</aff>
                <aff id="aff8"><label>8</label>Department of Pediatric Nephrology, Manchester Children’s Hospital, Manchester, UK</aff>
                <aff id="aff9"><label>9</label>Department of Pediatric Nephrology, Great North Children’s Hospital, Newcastle, UK</aff>
                <aff id="aff10"><label>10</label>Department of Pediatric Nephrology, Birmingham Children’s Hospital, Birmingham, UK</aff>
                <aff id="aff11"><label>11</label>Department of Pediatric Nephrology, Evelina Childrens Hospital, London, UK</aff>
                <aff id="aff12"><label>12</label>Department of Pediatric Nephrology, Leeds Teaching Hospitals NHS Foundation Trust, Leeds, UK</aff>
                <aff id="aff13"><label>13</label>Department of Pediatric Nephrology, Glasgow Hospital for Sick Children, Glasgow, UK</aff>
                <aff id="aff14"><label>14</label>Department of Data Research Innovation and Virtual Environments, Great Ormond Street Hospital for Children, London, UK</aff>
                <aff id="aff15"><label>15</label>Department of Psychology, Great Ormond Street Hospital for Children, London, UK</aff>
                <aff id="aff16"><label>16</label>Pediatric Intensive Care Unit, Great Ormond Street Hospital for Children, London, UK</aff>
              </contrib-group>
              <author-notes>
                <corresp id="cor1"><label>∗</label><bold>Correspondence:</bold> Wesley N. Hayes, Department of Pediatric Nephrology, Great Ormond Street Hospital NHS Foundation Trust, London WC1N 3JH, UK. <email>wesley.hayes@gosh.nhs.uk</email></corresp>
              </author-notes>
              <pub-date pub-type="pmc-release">
                <day>1</day>
                <month>2</month>
                <year>2024</year>
              </pub-date>
              <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="ppub">.-->
              <pub-date pub-type="ppub">
                <month>2</month>
                <year>2024</year>
              </pub-date>
              <volume>105</volume>
              <issue>2</issue>
              <fpage>364</fpage>
              <lpage>375</lpage>
              <history>
                <date date-type="received">
                  <day>12</day>
                  <month>5</month>
                  <year>2023</year>
                </date>
                <date date-type="rev-recd">
                  <day>7</day>
                  <month>9</month>
                  <year>2023</year>
                </date>
                <date date-type="accepted">
                  <day>24</day>
                  <month>9</month>
                  <year>2023</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© 2023 International Society of Nephrology. Published by Elsevier Inc.</copyright-statement>
                <copyright-year>2023</copyright-year>
                <copyright-holder>International Society of Nephrology</copyright-holder>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref>
                  <license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p>
                </license>
              </permissions>
              <abstract id="abs0010">
                <p>Acute electrolyte and acid-base imbalance is experienced by many children following kidney transplant. This is partly because doctors give very large volumes of artificial fluids to keep the new kidney working. When severe, fluid imbalance can lead to seizures, cerebral edema and death. In this pragmatic, open-label, randomized controlled trial, we randomly assigned (1:1) pediatric kidney transplant recipients to Plasma-Lyte-148 or standard of care perioperative intravenous fluids (predominantly 0.45% sodium chloride and 0.9% sodium chloride solutions). We then compared clinically significant electrolyte and acid-base abnormalities in the first 72 hours post-transplant. The primary outcome, acute hyponatremia, was experienced by 53% of 68 participants in the Plasma-Lyte-148 group and 58% of 69 participants in the standard fluids group (odds ratio 0·77 (0·34 - 1·75)). Five of 16 secondary outcomes differed with Plasma-Lyte-148: hypernatremia was significantly more frequent (odds ratio 3·5 (1·1 – 10·8)), significantly fewer changes to fluid prescriptions were made (rate ratio 0·52 (0·40-0·67)), and significantly fewer participants experienced hyperchloremia (odds ratio 0·17 (0·07 – 0·40)), acidosis (odds ratio 0·09 (0·04 - 0·22)) and hypomagnesemia (odds ratio 0·21 (0·08 – 0·50)). No other secondary outcomes differed between groups. Serious adverse events were reported in 9% of participants randomized to Plasma-Lyte-148 and 7% of participants randomized to standard fluids. Thus, perioperative Plasma-Lyte-148 did not change the proportion of children who experienced acute hyponatremia compared to standard fluids. However fewer fluid prescription changes were made with Plasma-Lyte-148, while hyperchloremia and acidosis were less common.</p>
              </abstract>
              <abstract abstract-type="graphical" id="abs0015">
                <title>Graphical abstract</title>
                <fig id="undfig1" position="anchor">
                  <graphic xlink:href="ga1"/>
                </fig>
              </abstract>
              <kwd-group id="kwrds0010">
                <title>Keywords</title>
                <kwd>hyponatremia</kwd>
                <kwd>pediatric nephrology</kwd>
                <kwd>transplantation</kwd>
              </kwd-group>
            </article-meta>
          </front>
          <body>
            <p id="p0010">
              <boxed-text id="dtbox1">
                <caption>
                  <title>Lay Summary</title>
                </caption>
                <p id="p0015">In the first few days after a kidney transplant, children can develop harmful changes in the balance of salt, water, and acid in the bloodstream. This is because physicians give large volumes of artificial fluids into the veins to keep the new kidney working. This research compared the standard fluids used after a transplant operation with an alternative called Plasma-Lyte. A total of 138 children from 9 hospitals took part. Half of them were randomly allocated to have standard fluids, and half of them were randomized to have Plasma-Lyte during and after their transplant operation. The number of children who developed low levels of sodium (the main salt in the blood) was similar with standard fluids and Plasma-Lyte. More children developed abnormal chloride and acid balance with standard fluids. More changes to fluid prescriptions were made by doctors for children allocated to standard fluids.</p>
              </boxed-text>
            </p>
            <p id="p0020">Transplantation is the treatment of choice for children with kidney failure.<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref> Acute electrolyte and acid-base imbalance is experienced by many pediatric recipients in the postoperative period.<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref> Abnormalities include acute hyponatremia, hyperkalemia, hyperchloremia, and metabolic acidosis; smaller recipients of deceased donor kidneys are most at risk.<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref></p>
            <p id="p0025">Acute hyponatremia is associated with clinical complications, including cerebral edema, seizures, and death.<xref rid="bib3" ref-type="bibr"><sup>3</sup></xref><sup>,</sup><xref rid="bib4" ref-type="bibr"><sup>4</sup></xref> Prepubertal children are at greater risk of complications from acute hyponatremia because of the relatively low ratio of cerebrospinal fluid and brain volume compared with older children and adults.<xref rid="bib5" ref-type="bibr"><sup>5</sup></xref><sup>,</sup><xref rid="bib6" ref-type="bibr"><sup>6</sup></xref> Acute hyponatremia also contributes to symptoms such as nausea, vomiting, and headaches.<xref rid="bib7" ref-type="bibr"><sup>7</sup></xref><sup>,</sup><xref rid="bib8" ref-type="bibr"><sup>8</sup></xref></p>
            <p id="p0030">In many other clinical circumstances, children receiving isotonic fluid rather than hypotonic fluid experience less hyponatremia.<xref rid="bib9" ref-type="bibr">9</xref>, <xref rid="bib10" ref-type="bibr">10</xref>, <xref rid="bib11" ref-type="bibr">11</xref>, <xref rid="bib12" ref-type="bibr">12</xref>, <xref rid="bib13" ref-type="bibr">13</xref>, <xref rid="bib14" ref-type="bibr">14</xref> National guidance recommends isotonic fluid for children in general pediatric care.<xref rid="bib15" ref-type="bibr"><sup>15</sup></xref> This guidance was not widely adopted in pediatric transplantation because of uncertainty about its applicability in this population, and i.v. fluids are changed regularly in response to results of frequent blood tests.</p>
            <p id="p0035">Plasma-Lyte-148 is an isotonic, gluconate-acetate buffered i.v. fluid containing 140 mEq sodium, 5 mEq potassium, 3 mEq magnesium, 98 mEq chloride, 27 mEq acetate, and 23 mEq gluconate per liter.<xref rid="bib16" ref-type="bibr"><sup>16</sup></xref> There is a physiological basis to expect that Plasma-Lyte would reduce the incidence of clinically significant electrolyte and acid-base abnormalities in children following kidney transplant compared with standard fluids. In critically ill adults, use of Plasma-Lyte reduced the incidence of a composite outcome of death, new kidney replacement therapy, or persistent kidney dysfunction compared with 0.9% sodium chloride; however, a subsequent study showed no difference in death or acute kidney injury in this population.<xref rid="bib17" ref-type="bibr"><sup>17</sup></xref><sup>,</sup><xref rid="bib18" ref-type="bibr"><sup>18</sup></xref> In noncritically ill adults, hospital-free days did not differ with use of Plasma-Lyte compared with 0.9% sodium chloride.<xref rid="bib19" ref-type="bibr"><sup>19</sup></xref> A randomized trial in children with sepsis comparing major adverse kidney events with use of balanced fluid versus 0.9% sodium chloride is currently underway.<xref rid="bib20" ref-type="bibr"><sup>20</sup></xref></p>
            <p id="p0040">The aim of the Plasma-Lyte Usage and Assessment of Kidney Transplant Outcomes in Children (PLUTO) trial was to determine whether the incidence of clinically significant plasma electrolyte and acid-base abnormalities in pediatric kidney transplant recipients differ with Plasma-Lyte-148 compared with the existing standard-of-care i.v. fluids.</p>
            <sec id="sec1">
              <title>Methods</title>
              <sec id="sec1.1">
                <title>Study design and setting</title>
                <p id="p0045">PLUTO was an investigator-initiated, open-label, randomized controlled trial comparing Plasma-Lyte-148 with current i.v. fluids in children receiving kidney transplants, conducted in 9 UK pediatric kidney transplant centers. A national Research Ethics Committee approved the study (Health Research Authority reference 19/LO/1866). Recruitment started on June 8, 2020, and was completed on August 9, 2022. The trial protocol was published previously.<xref rid="bib21" ref-type="bibr"><sup>21</sup></xref></p>
              </sec>
              <sec id="sec1.2">
                <title>Participants</title>
                <p id="p0050">Patients aged &lt;18 years receiving a kidney-only transplant from either a living or deceased donor were eligible to participate. Multiorgan transplants were excluded. The trial was discussed with patients and parents/guardians in advance of kidney transplant, and they gave informed written consent and assent as appropriate, which was confirmed on the day of transplant. Baseline demographic data were obtained directly from the UK Transplant Registry, held by National Health Service (NHS) Blood and Transplant.</p>
              </sec>
              <sec id="sec1.3">
                <title>Randomization</title>
                <p id="p0055">Participants were randomized 1:1 to the intervention or control groups on the day of transplant using an online system. Randomization was stratified by transplant center and patient weight (&lt;20 vs. ≥20 kg), and further balanced within blocks of varying, undisclosed sizes. The randomization list was produced by the trial statistician using SAS statistical software.</p>
              </sec>
              <sec id="sec1.4">
                <title>Procedures</title>
                <p id="p0060">Participants randomized to the intervention group received either Plasma-Lyte-148 or Plasma-Lyte-148 and glucose 5%, which could be administered interchangeably at the discretion of the clinical team, both intraoperatively and postoperatively. Participants randomized to the control group received standard i.v. fluids used at the site. Standard i.v. fluid practice varied between sites and included 0.45% and 0.9% sodium chloride solutions, Hartmann solution, human albumin solution, and colloid solutions. All sites changed the composition of i.v. fluid in response to regular blood test monitoring. Neither Plasma-Lyte-148 nor Plasma-Lyte-148 and glucose 5% could be administered in the control group. The volume and rate of infusion of i.v. fluid, and the time to change from i.v. to enteral fluid, were decided by the treating clinician.</p>
                <p id="p0065">With the exception of i.v. fluid composition, all participants received standard clinical transplant care.</p>
                <p id="p0070">Participants were assessed daily in the hospital for the first 72 hours post-transplant, at hospital discharge, and at their 3-month clinic follow-up visit. Clinical data and adverse events were captured using a secure web-based electronic case report form in the trial database (MACRO). Laboratory results for 72 hours following the start of the transplant operation were downloaded directly from the laboratory information management systems at each site, then uploaded to a secure web-based platform. Three-month follow-up data were obtained directly from the UK Transplant Registry. Data quality was assured by regular independent central and on-site monitoring.</p>
              </sec>
              <sec id="sec1.5">
                <title>Outcomes</title>
                <p id="p0075">The primary outcome measure was acute hyponatremia within the first 72 hours post-transplant, defined as any laboratory plasma sodium concentration &lt;135 mmol/L.</p>
                <p id="p0080">Secondary outcomes included hypernatremia (defined as plasma sodium concentration &gt;145 mmol/l), hyperkalemia (plasma potassium &gt;5.5 mmol/L), hypokalemia (plasma potassium &lt;3.5 mmol/L), non–anion gap acidosis (plasma bicarbonate &lt;20 mmol/L and anion gap &lt;20 mmol/L), hyperglycemia (random blood glucose &gt;5.5 mmol/L), hypomagnesemia (plasma magnesium &lt;0.7 mmol/L), hyperchloremia (plasma chloride &gt;107 mmol/L), excessive rate of reduction in plasma sodium concentration (defined as &gt;1 mmol/L per hour averaged over 6 hours), excessive magnitude of reduction in plasma sodium concentration (defined as &gt;10 mmol/L from pretransplant level), symptoms of hyponatremia, maximum and minimum systolic blood pressure, degree of fluid overload (defined as maximal proportional increase in weight from pretransplant weight), time to discharge from hospital, transplant kidney function (estimated glomerular filtration rate at 1, 3, and 7 days), and the number of changes in i.v. fluid (defined by changes to the type of fluid prescribed and administered) within the first 72 hours post-transplant.</p>
                <p id="p0085">Safety reporting included notification of serious adverse events to NHS Blood and Transplant Clinical Trials Unit within 24 hours. We used the Common Terminology Criteria of Adverse Events classification. A list of predefined serious adverse events unrelated to fluid composition were excluded from reporting, including surgical, infective, immunologic, and medication-related complications.<xref rid="bib21" ref-type="bibr"><sup>21</sup></xref> Serious adverse events were monitored regularly by the independent data monitoring committee to ensure ongoing safety of trial participants.</p>
              </sec>
              <sec id="sec1.6">
                <title>Statistical analysis</title>
                <p id="p0090">On the basis of published cohort data and a Cochrane meta-analysis, we assumed a 59% incidence of hyponatremia in the standard fluid group, with a reduction to 29.5% with Plasma-Lyte-148 fluid.<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref><sup>,</sup><xref rid="bib9" ref-type="bibr"><sup>9</sup></xref> The sample size required to detect this difference with 90% power using a 2-sided test, 5% type I error, and 1:1 allocation, allowing for 2 formal interim analyses for harm or benefit, was 128 participants. Allowing for 10% attrition, the total number of participants required was 144. The sample size was based on an unadjusted log odds ratio test (with interim analyses, as described above).</p>
                <p id="p0095">For all analyses, participants were analyzed according to their allocated arm. Analysis for all efficacy outcomes was performed in a modified intention-to-treat cohort, which included all randomized participants who received a transplant (excluding those who did not undergo transplant and therefore had no outcome data). An additional per-protocol analysis was performed of the primary outcome, which also excluded those withdrawn, randomized in error, or who had a protocol deviation. Safety analyses included all randomized participants who underwent a transplant.</p>
                <p id="p0100">The proportion of participants who experienced hyponatremia was analyzed using a logistic regression model adjusting for donor type (living vs. deceased donor), participant weight (&lt;20 vs. ≥20 kg pretransplant), and transplant center as a random effect. A prespecified subgroup analysis of the primary outcome split the standard fluids group into participants who received &gt;50% versus ≤50% 0.9% sodium chloride fluid by total volume. Two prespecified sensitivity analyses of the primary outcome were performed: an unadjusted analysis and acute hyponatremia, as identified in plasma or blood gas, rather than plasma alone.</p>
                <p id="p0105">Secondary outcomes that assessed the incidence of other electrolyte and acid-base disturbance were analyzed using the same model as the primary outcome, although adjustment factors differed on the basis of model convergence, following a predefined approach. Adjusted normal linear regression models were used to assess differences in the continuous secondary outcomes, adjusting for repeated measures (by additionally incorporating a participant random effect within sites) where appropriate; an adjusted negative binomial model was used to compare number of changes in the i.v. fluid composition, and an adjusted Cox proportional hazards model was used to assess differences in time to discharge.</p>
                <p id="p0110">An independent Data Monitoring Committee oversaw the safety data and interim analyses. To preserve the overall 5% type I error rate for the trial and allow early stopping of the trial in the case of strong evidence for harm or benefit, the trial used a group sequential design with O’Brien Fleming boundaries, resulting in a significance level of <italic>P</italic> &lt; 0.0422 at the final analysis. Two formal interim analyses were conducted after 70 and 100 randomizations, after allowing time for primary outcome data to be obtained. The stopping boundaries were used as a guideline alongside other safety data available to the committee and used as part of their overall assessment of the trial.</p>
                <p id="p0115">The statistical analysis plan was finalized before data were made available and results were analyzed. Statistical analyses were performed using SAS version 9.4M5. For all analyses, <italic>P</italic> &lt; 0.05 was considered statistically significant. No adjustments were made to account for multiple testing, so results for secondary outcome analyses should be considered hypothesis generating only. The trial is registered with the International Standard Randomised Controlled Trial Number (ISCTRN) registry (16586164), the European Union Clinical Trials Register (EudraCT: 2019-003025-22), and the Cochrane Central Register of Controlled Trials (CN-02070104).</p>
              </sec>
            </sec>
            <sec id="sec2">
              <title>Results</title>
              <p id="p0120">Between June 8, 2020, and August 9, 2022, 238 children were assessed for trial eligibility (<xref rid="fig1" ref-type="fig">Figure 1</xref>). A total of 148 consented, and 144 were randomized (72 [50%] to the Plasma-Lyte-148 group and 72 [50%] to the standard fluids group; <xref rid="fig1" ref-type="fig">Figure 1</xref>). One hundred and thirty-seven participants (68 in the Plasma-Lyte-148 group and 69 in the standard fluids group) proceeded to transplant and were included in the primary outcome analysis. Three participants in each group were excluded after randomization due to not undergoing transplantation, and 1 participant in the Plasma-Lyte-148 group was excluded from the primary analysis due to missing data. Baseline participant and transplant characteristics are summarized in <xref rid="tbl1" ref-type="table">Tables 1</xref> and <xref rid="tbl2" ref-type="table">2</xref>, respectively. The volumes and types of i.v. fluids received are summarized in <xref rid="tbl3" ref-type="table">Table 3</xref>; participants in the standard fluids group received predominantly 0.45% sodium chloride and 0.9% sodium chloride solutions. Medication and blood products received are summarized in <xref rid="appsec1" ref-type="sec">Supplementary Table S1</xref>.<fig id="fig1"><label>Figure 1</label><caption><p><bold>Trial profile.</bold> Time could have elapsed between patients being approached in the clinic and confirmed assent or consent at transplantation (depending on site practice). Therefore, not all approached patients had been consented or randomized when recruitment was stopped. <sup>a</sup>Other reasons included screened by sites for eligibility and approach, approached but no further details provided, and where no reason for decline or further details were provided. PLUTO, Plasma-Lyte Usage and Assessment of Kidney Transplant Outcomes in Children.</p></caption><graphic xlink:href="gr1"/></fig><table-wrap position="float" id="tbl1"><label>Table 1</label><caption><p>Baseline characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Participant characteristic</th><th colspan="2">Randomized treatment<hr/></th><th rowspan="2">Total (n = 138)</th></tr><tr><th>Standard care (n = 69)</th><th>Plasma-Lyte-148 (n = 69)</th></tr></thead><tbody><tr><td>Age, yr</td><td align="char">11 (6–14)</td><td align="char">10 (6–15)</td><td align="char">11 (6–14)</td></tr><tr><td>Male sex</td><td align="char">39 (57)</td><td align="char">37 (54)</td><td align="char">76 (55)</td></tr><tr><td>Ethnic origin</td><td/><td/><td/></tr><tr><td> Asian</td><td align="char">10 (14)</td><td align="char">9 (14)</td><td align="char">19 (14)</td></tr><tr><td> Black</td><td align="char">5 (7)</td><td align="char">7 (11)</td><td align="char">12 (9)</td></tr><tr><td> Mixed</td><td align="char">1 (1)</td><td align="char">2 (3)</td><td align="char">3 (2)</td></tr><tr><td> White</td><td align="char">47 (68)</td><td align="char">38 (58)</td><td align="char">85 (63)</td></tr><tr><td> Other</td><td align="char">2 (3)</td><td align="char">4 (6)</td><td align="char">6 (4)</td></tr><tr><td> Unknown</td><td align="char">4 (6)</td><td align="char">6 (9)</td><td align="char">10 (7)</td></tr><tr><td>Cause of end-stage kidney disease</td><td/><td/><td/></tr><tr><td> Tubulointerstitial disease (CAKUT/non-CAKUT)</td><td align="char">29 (42)</td><td align="char">29 (42)</td><td align="char">58 (42)</td></tr><tr><td> Glomerular disease</td><td align="char">4 (6)</td><td align="char">8 (12)</td><td align="char">12 (9)</td></tr><tr><td> Hereditary nephropathies</td><td align="char">6 (9)</td><td align="char">6 (9)</td><td align="char">12 (9)</td></tr><tr><td> Systemic diseases</td><td align="char">2 (3)</td><td align="char">6 (9)</td><td align="char">8 (6)</td></tr><tr><td> Other</td><td align="char">28 (41)</td><td align="char">20 (29)</td><td align="char">48 (35)</td></tr><tr><td>Native urine output, ml/kg per 24 h</td><td align="char">16 (0–43)</td><td align="char">5 (0–29)</td><td align="char">10 (0–37)</td></tr><tr><td>Dialysis type</td><td/><td/><td/></tr><tr><td> Hemodialysis</td><td align="char">24 (35)</td><td align="char">27 (39)</td><td align="char">51 (37)</td></tr><tr><td> Peritoneal dialysis</td><td align="char">25 (36)</td><td align="char">30 (43)</td><td align="char">55 (40)</td></tr><tr><td> Preemptive</td><td align="char">20 (29)</td><td align="char">12 (17)</td><td align="char">32 (23)</td></tr><tr><td>Weight, kg</td><td align="char">33 (18–48)</td><td align="char">32 (17–48)</td><td align="char">32 (17–48)</td></tr><tr><td>Height, cm</td><td align="char">140 (106–155)</td><td align="char">135 (108–156)</td><td align="char">139 (106–155)</td></tr><tr><td>BMI, kg/m<sup>2</sup></td><td align="char">17 (16–20)</td><td align="char">17 (15–19)</td><td align="char">17 (15–19)</td></tr><tr><td>Systolic blood pressure, mm Hg<xref rid="tbl1fna" ref-type="table-fn">a</xref></td><td align="char">119 (108–128)</td><td align="char">120 (110–131)</td><td align="char">120 (109–130)</td></tr><tr><td>Blood group</td><td/><td/><td/></tr><tr><td> O</td><td align="char">28 (41)</td><td align="char">29 (43)</td><td align="char">57 (42)</td></tr><tr><td> A</td><td align="char">29 (42)</td><td align="char">19 (28)</td><td align="char">48 (35)</td></tr><tr><td> B</td><td align="char">6 (9)</td><td align="char">17 (25)</td><td align="char">23 (17)</td></tr><tr><td> AB</td><td align="char">6 (9)</td><td align="char">3 (4)</td><td align="char">9 (7)</td></tr><tr><td>Recipient waiting time (if deceased donor transplant), d</td><td align="char">671 (346–1011)</td><td align="char">680 (329–1230)</td><td align="char">671 (333–1084)</td></tr><tr><td>cRF, %</td><td align="char">0 (0–47)</td><td align="char">0 (0–3)</td><td align="char">0 (0–33)</td></tr><tr><td>Graft number</td><td/><td/><td/></tr><tr><td> First</td><td align="char">61 (88)</td><td align="char">65 (96)</td><td align="char">126 (92)</td></tr><tr><td> Second</td><td align="char">8 (12)</td><td align="char">3 (4)</td><td align="char">11 (8)</td></tr></tbody></table><table-wrap-foot><fn id="tspara0015"><p>BMI, body mass index; CAKUT, congenital abnormalities of the kidney and urinary tract; cRF, calculated reaction frequency.</p></fn><fn id="tspara0020"><p>Data are given as number (percentage) for categorical variables and median (interquartile range) for continuous variables. Summary of missing data: ethnicity is missing for 3 participants; native urine output is missing for 12 participants; height and BMI are missing for 4 participants; systolic blood pressure, blood group, cRF, and graft number are missing for 1 participant; and age, sex recorded in patient's clinical patient record, cause of end-stage kidney disease, dialysis type, weight, and waiting time are missing for no participants.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl1fna"><label>a</label><p id="ntpara0010">Maximum of 3 measurements at baseline for each participant.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="tbl2"><label>Table 2</label><caption><p>Transplant characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Characteristic</th><th colspan="2">Randomized treatment<hr/></th><th rowspan="2">Total (n = 138)</th></tr><tr><th>Standard care (n = 69)</th><th>Plasma-Lyte-148 (n = 69)</th></tr></thead><tbody><tr><td>Cold ischemia time, h<xref rid="tbl2fna" ref-type="table-fn">a</xref></td><td/><td/><td/></tr><tr><td> Deceased donor</td><td align="char">11 (9–13)</td><td align="char">12 (11–15)</td><td align="char">11 (9–14)</td></tr><tr><td> Living donor</td><td align="char">4 (3–5)</td><td align="char">4 (3–5)</td><td align="char">4 (3–5)</td></tr><tr><td>HLA mismatch (at A, B, or DR locus)</td><td/><td/><td/></tr><tr><td> 000</td><td align="char">6 (9)</td><td align="char">6 (10)</td><td align="char">12 (10)</td></tr><tr><td> 0 DR and 0/1 B</td><td align="char">29 (45)</td><td align="char">21 (35)</td><td align="char">50 (40)</td></tr><tr><td> 0 DR and 2 B or 1 DR and 0/1 B</td><td align="char">26 (41)</td><td align="char">32 (53)</td><td align="char">58 (47)</td></tr><tr><td> 1 DR and 2 B or 2 DR</td><td align="char">3 (5)</td><td align="char">1 (2)</td><td align="char">4 (3)</td></tr><tr><td>Graft placement</td><td/><td/><td/></tr><tr><td> Intra-abdominal</td><td align="char">16 (23)</td><td align="char">8 (12)</td><td align="char">24 (17)</td></tr><tr><td> Extraperitoneal</td><td align="char">53 (77)</td><td align="char">61 (88)</td><td align="char">114 (83)</td></tr><tr><td>Destination of transfer from operation theater</td><td/><td/><td/></tr><tr><td> PICU</td><td align="char">32 (46)</td><td align="char">37 (54)</td><td align="char">69 (50)</td></tr><tr><td> Ward</td><td align="char">37 (54)</td><td align="char">32 (46)</td><td align="char">69 (50)</td></tr><tr><td>Donor characteristics</td><td/><td/><td/></tr><tr><td>Donor type</td><td/><td/><td/></tr><tr><td> DBD</td><td align="char">25 (36)</td><td align="char">20 (29)</td><td align="char">45 (33)</td></tr><tr><td> DCD</td><td align="char">4 (6)</td><td align="char">6 (9)</td><td align="char">10 (7)</td></tr><tr><td> Living</td><td align="char">40 (58)</td><td align="char">42 (62)</td><td align="char">82 (60)</td></tr><tr><td>Donor age, yr</td><td align="char">38 (32–47)</td><td align="char">38 (30–42)</td><td align="char">38 (31–43)</td></tr><tr><td>Donor ethnicity</td><td/><td/><td/></tr><tr><td> Asian</td><td align="char">5 (7)</td><td align="char">11 (16)</td><td align="char">16 (12)</td></tr><tr><td> Black</td><td align="char">3 (4)</td><td align="char">2 (3)</td><td align="char">5 (4)</td></tr><tr><td> Mixed</td><td align="char">0 (0)</td><td align="char">0 (0)</td><td align="char">0 (0)</td></tr><tr><td> White</td><td align="char">55 (82)</td><td align="char">50 (75)</td><td align="char">105 (78)</td></tr><tr><td> Other</td><td align="char">4 (6)</td><td align="char">4 (6)</td><td align="char">8 (6)</td></tr><tr><td> Unknown</td><td align="char">0 (0)</td><td align="char">0 (0)</td><td align="char">0 (0)</td></tr><tr><td>Donor BMI, kg/m<sup>2</sup></td><td align="char">24 (21–28)</td><td align="char">27 (23–30)</td><td align="char">26 (22–29)</td></tr><tr><td>Blood group match</td><td/><td/><td/></tr><tr><td> Identical</td><td align="char">54 (78)</td><td align="char">55 (81)</td><td align="char">109 (80)</td></tr><tr><td> Compatible</td><td align="char">14 (20)</td><td align="char">9 (13)</td><td align="char">23 (17)</td></tr><tr><td> Incompatible</td><td align="char">1 (1)</td><td align="char">4 (6)</td><td align="char">5 (4)</td></tr></tbody></table><table-wrap-foot><fn id="tspara0030"><p>BMI, body mass index; DBD, donation after brain death; DCD, donation after circulatory death; HLA, human leukocyte antigen; PICU, pediatric intensive care unit.</p></fn><fn id="tspara0035"><p>Data are given as number (percentage) for categorical variables and median (interquartile range) for continuous variables. Summary of missing data: cold ischemia time is missing for 7 participants; HLA mismatch is missing for 14 participants; donor BMI is missing for 15 participants; donor type, donor age, and blood group match is missing for 1 participant; donor ethnicity is missing for 4 participants; and graft placement and destination of transfer from operation theater is missing for no participants.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl2fna"><label>a</label><p id="ntpara0015">Elapsed time from start of perfusion to time kidney was perfused with recipient’s blood.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="tbl3"><label>Table 3</label><caption><p>Volume of i.v. fluids received</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="2" rowspan="2">Summary of i.v. fluid volume received</th><th colspan="2">Randomized treatment<hr/></th><th rowspan="2">Total (n = 138)</th></tr><tr><th>Standard care (n = 69)</th><th>Plasma-Lyte-148 (n = 69)</th></tr></thead><tbody><tr><td colspan="2">N (%) of participants who received at least 1 i.v. fluid</td><td>69 (100)</td><td>69 (100)</td><td>138 (100)</td></tr><tr><td colspan="2">Median (IQR) i.v. fluid volume per participant per occasion, ml/kg body weight</td><td>19 (9–52)</td><td>23 (10–63)</td><td>20 (9–58)</td></tr><tr><td colspan="5">Total i.v. fluid volume received per participant by time period, median (IQR), ml/kg body weight</td></tr><tr><td colspan="2"> Intraoperatively</td><td>73 (50–98)</td><td>77 (55–104)</td><td>74 (53–101)</td></tr><tr><td colspan="2"> Day 1</td><td>132 (99–221)</td><td>149 (91–215)</td><td>137 (94–219)</td></tr><tr><td colspan="2"> Day 2</td><td>54 (15–104)</td><td>51 (25–86)</td><td>52 (17–92)</td></tr><tr><td colspan="2"> Day 3</td><td>18 (7–46)</td><td>20 (13–38)</td><td>19 (11–40)</td></tr><tr><td colspan="2">All (intraoperatively to 72 h post-transplant)</td><td>284 (195–371)</td><td>267 (201–385)</td><td>273 (195–385)</td></tr><tr><td colspan="5">Total i.v. fluid volume per participant by fluid type, ml/kg body weight</td></tr><tr><td rowspan="2"> Plasma-Lyte-148</td><td>n</td><td>5</td><td>68</td><td>73</td></tr><tr><td>Median (IQR)</td><td>43 (9–55)</td><td>248 (180–342)</td><td>242 (168–318)</td></tr><tr><td/><td/><td/><td/><td/></tr><tr><td rowspan="2"> Plasma-Lyte-148 and 5% glucose</td><td>n</td><td>0</td><td>38</td><td>38</td></tr><tr><td>Median (IQR)</td><td/><td>32 (12–51)</td><td>32 (12–51)</td></tr><tr><td/><td/><td/><td/><td/></tr><tr><td rowspan="2"> 0.9% Sodium chloride</td><td>n</td><td>59</td><td>7</td><td>66</td></tr><tr><td>Median (IQR)</td><td>87 (41–172)</td><td>30 (7–36)</td><td>83 (33–164)</td></tr><tr><td/><td/><td/><td/><td/></tr><tr><td rowspan="2"> 0.9% Sodium chloride with 5% glucose</td><td>n</td><td>11</td><td>0</td><td>11</td></tr><tr><td>Median (IQR)</td><td>22 (10–58)</td><td/><td>22 (10–58)</td></tr><tr><td/><td/><td/><td/><td/></tr><tr><td rowspan="2"> 0.45% Sodium chloride</td><td>n</td><td>40</td><td>1</td><td>41</td></tr><tr><td>Median (IQR)</td><td>57 (22–178)</td><td>63 (63–63)</td><td>61 (23–169)</td></tr><tr><td/><td/><td/><td/><td/></tr><tr><td rowspan="2"> 0.45% Sodium chloride with 2.5% glucose</td><td>n</td><td>41</td><td>1</td><td>42</td></tr><tr><td>Median (IQR)</td><td>71 (19–140)</td><td>92 (92–92)</td><td>78 (19–140)</td></tr><tr><td/><td/><td/><td/><td/></tr><tr><td rowspan="2"> 0.45% Sodium chloride with 5% glucose</td><td>n</td><td>19</td><td>0</td><td>19</td></tr><tr><td>Median (IQR)</td><td>26 (17–55)</td><td/><td>26 (17–55)</td></tr><tr><td/><td/><td/><td/><td/></tr><tr><td rowspan="2"> 10% Glucose</td><td>n</td><td>10</td><td>4</td><td>14</td></tr><tr><td>Median (IQR)</td><td>11 (2–32)</td><td>6 (5–9)</td><td>7 (4–15)</td></tr><tr><td/><td/><td/><td/><td/></tr><tr><td rowspan="2"> 4.5% Human albumin solution</td><td>n</td><td>7</td><td>1</td><td>8</td></tr><tr><td>Median (IQR)</td><td>30 (15–52)</td><td>17 (17–17)</td><td>24 (16–47)</td></tr><tr><td/><td/><td/><td/><td/></tr><tr><td rowspan="2"> 5% Human albumin solution</td><td>n</td><td>3</td><td>3</td><td>6</td></tr><tr><td>Median (IQR)</td><td>20 (11–39)</td><td>5 (5–8)</td><td>9 (5–20)</td></tr><tr><td/><td/><td/><td/><td/></tr><tr><td rowspan="2"> Hartmann (Ringer lactate) solution</td><td>n</td><td>38</td><td>3</td><td>41</td></tr><tr><td>Median (IQR)</td><td>63 (44–93)</td><td>90 (18–192)</td><td>64 (44–93)</td></tr><tr><td/><td/><td/><td/><td/></tr><tr><td rowspan="2"> Geloplasma</td><td>n</td><td>0</td><td>0</td><td>0</td></tr><tr><td>Median (IQR)</td><td/><td/><td/></tr><tr><td/><td/><td/><td/><td/></tr><tr><td rowspan="2"> Other</td><td>n</td><td>10</td><td>2</td><td>12</td></tr><tr><td>Median (IQR)</td><td>9 (4–13)</td><td>7 (4–9)</td><td>9 (4–13)</td></tr></tbody></table><table-wrap-foot><fn id="tspara0045"><p>IQR, interquartile range.</p></fn><fn id="tspara0050"><p>n is calculated only for those with fluid volumes reported. Instances where fluids were reported without corresponding volumes were excluded.</p></fn></table-wrap-foot></table-wrap></p>
              <p id="p0125">In the primary modified intention-to-treat analysis, 36 of 68 (53%) participants in the Plasma-Lyte group and 40 of 69 (58%) participants in the standard fluids group experienced acute hyponatremia (odds ratio [OR], 0.77; 95% confidence interval [CI], 0.34–1.75; <italic>P</italic> = 0.53; <xref rid="tbl4" ref-type="table">Table 4</xref> and <xref rid="fig2" ref-type="fig">Figure 2</xref>). Similarly, per-protocol analysis of the primary outcome showed no difference in acute hyponatremia; 31 of 52 (60%) in the Plasma-Lyte group versus 38 of 62 (61%) in the standard fluid group (OR, 0.80; 95% CI, 0.32–2.01; <italic>P</italic> = 0.63; <xref rid="tbl4" ref-type="table">Table 4</xref>). A subgroup analysis that divided participants randomized to standard fluids into groups who received &gt;50% versus ≤50% 0.9% sodium chloride, and sensitivity analyses that included all blood gas sodium results and an unadjusted analysis, confirmed no significant difference in acute hyponatremia between participants randomized to Plasma-Lyte-148 versus standard fluids (<xref rid="appsec1" ref-type="sec">Supplementary Tables S2</xref> and <xref rid="appsec1" ref-type="sec">S3</xref>). Symptoms of hyponatremia, time to hyponatremia, duration of hyponatremia, and magnitude and rate of change of plasma sodium concentration were similar between groups (<xref rid="appsec1" ref-type="sec">Supplementary Tables S4</xref> and <xref rid="appsec1" ref-type="sec">S5</xref>). The distribution of lowest plasma sodium concentration per participant per day is illustrated in <xref rid="fig3" ref-type="fig">Figure 3</xref>.<table-wrap position="float" id="tbl4"><label>Table 4</label><caption><p>Primary outcome: acute hyponatremia</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"/><th colspan="2">Randomized treatment<hr/></th><th rowspan="2">Total (n = 137)</th></tr><tr><th>Standard care (n = 69)</th><th>Plasma-Lyte-148 (n = 68)</th></tr></thead><tbody><tr><td>Modified intention-to-treat analysis</td><td/><td/><td/></tr><tr><td> n/N (%)</td><td>40/69 (58)</td><td>36/68 (53)</td><td>76/137 (55)</td></tr><tr><td> OR (95% CI)<xref rid="tbl4fna" ref-type="table-fn">a</xref></td><td/><td>0.77 (0.34 to 1.75)</td><td/></tr><tr><td> <italic>P</italic> value<xref rid="tbl4fnb" ref-type="table-fn">b</xref></td><td/><td>0.5274</td><td/></tr><tr><td> Unadjusted risk difference (95% CI), %</td><td/><td>–5 (–22 to 12)</td><td/></tr><tr><td> No. of events, median (IQR)<xref rid="tbl4fnc" ref-type="table-fn">c</xref></td><td>1.0 (1.0 to 2.0)</td><td>1.0 (1.0 to 2.0)</td><td>1.0 (1.0 to 2.0)</td></tr><tr><td/><td/><td/><td/></tr><tr><td>Per-protocol analysis<xref rid="tbl4fnd" ref-type="table-fn">d</xref></td><td/><td/><td/></tr><tr><td> n/N (%)</td><td>38/62 (61)</td><td>31/52 (60)</td><td>69/114 (61)</td></tr><tr><td> OR (95% CI)<xref rid="tbl4fna" ref-type="table-fn">a</xref></td><td/><td>0.80 (0.32 to 2.01)</td><td/></tr><tr><td> <italic>P</italic> value<xref rid="tbl4fnb" ref-type="table-fn">b</xref></td><td/><td>0.6287</td><td/></tr><tr><td> No. of events, median (IQR)<xref rid="tbl4fnc" ref-type="table-fn">c</xref></td><td>1.0 (1.0 to 2.0)</td><td>1.0 (1.0 to 2.0)</td><td>1.0 (1.0 to 2.0)</td></tr></tbody></table><table-wrap-foot><fn><p>CI, confidence interval; IQR, interquartile range; OR, odds ratio.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl4fna"><label>a</label><p id="ntpara0020">Mixed logistic regression model adjusted for site, participant weight pretransplant, and donor type.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl4fnb"><label>b</label><p id="ntpara0025"><italic>P</italic> value from the likelihood ratio test when including and excluding the treatment term from the model.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl4fnc"><label>c</label><p id="ntpara0030">Per participant with at least 1 event.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl4fnd"><label>d</label><p id="ntpara0035">Per-protocol analysis excluded those withdrawn (n = 1), randomized in error (n = 0), and who had a protocol deviation (n = 24, of which 23 were fluid deviations). Participants may fall into &gt;1 of the exclusion criteria.</p></fn></table-wrap-foot></table-wrap><fig id="fig2"><label>Figure 2</label><caption><p><bold>Primary and secondary electrolyte outcomes.</bold> Tornado and forest plot illustrating the number and proportion of participants who experienced the outcome alongside the adjusted odds ratio and 95% confidence interval (CI).</p></caption><graphic xlink:href="gr2"/></fig><fig id="fig3"><label>Figure 3</label><caption><p><bold>Other outcomes.</bold> Lowest plasma sodium per participant per day, highest plasma chloride per participant per day, and highest plasma potassium per participant per day, for the first 72 hours post-transplant.</p></caption><graphic xlink:href="gr3"/></fig></p>
              <p id="p0130">The proportion of participants who experienced non–anion gap acidosis was significantly lower in the Plasma-Lyte group: 12 of 63 (19%) participants in the Plasma-Lyte group versus 44 of 64 (69%) participants in the standard fluid group (OR, 0.09; 95% CI, 0.04–0.22; <italic>P</italic> &lt; 0.0001; <xref rid="tbl5" ref-type="table">Table 5</xref> and <xref rid="fig2" ref-type="fig">Figure 2</xref>). Fewer participants in the Plasma-Lyte group developed hyperchloremia (36/68 [53%]) than the standard fluid group (59/69 [86%]) (OR, 0.17; 95% CI, 0.07–0.40; <italic>P</italic> &lt; 0.0001; <xref rid="tbl5" ref-type="table">Table 5</xref> and <xref rid="fig2" ref-type="fig">Figure 2</xref>).<table-wrap position="float" id="tbl5"><label>Table 5</label><caption><p>Secondary outcomes: other electrolyte and acid-base abnormalities</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"/><th colspan="2">Randomized treatment<hr/></th><th rowspan="2">Total (n = 138)</th></tr><tr><th>Standard care (n = 69)</th><th>Plasma-Lyte-148 (n = 69)</th></tr></thead><tbody><tr><td><bold>Other electrolyte abnormalities within the first 72 h post-transplantation</bold></td><td/><td/><td/></tr><tr><td>Hypernatremia</td><td/><td/><td/></tr><tr><td> Participants, n/N (%)</td><td>8/69 (12)</td><td>17/68 (25)</td><td>25/137 (18)</td></tr><tr><td> OR (95% CI)<xref rid="tbl5fna" ref-type="table-fn">a</xref></td><td/><td>3.47 (1.12–10.74)</td><td/></tr><tr><td> <italic>P</italic> value<xref rid="tbl5fnb" ref-type="table-fn">b</xref></td><td/><td>0.0223</td><td/></tr><tr><td> No. of events, median (IQR)<xref rid="tbl5fnc" ref-type="table-fn">c</xref></td><td>1.0 (1.0–2.0)</td><td>1.0 (1.0–2.0)</td><td>1.0 (1.0–2.0)</td></tr><tr><td>Hyperkalemia</td><td/><td/><td/></tr><tr><td> Participants, n/N (%)</td><td>17/69 (25)</td><td>18/68 (26)</td><td>35/137 (26)</td></tr><tr><td> OR (95% CI)<xref rid="tbl5fna" ref-type="table-fn">a</xref></td><td/><td>1.23 (0.52–2.88)</td><td/></tr><tr><td> <italic>P</italic> value<xref rid="tbl5fnb" ref-type="table-fn">b</xref></td><td/><td>0.6369</td><td/></tr><tr><td> No. of events, median (IQR)<xref rid="tbl5fnc" ref-type="table-fn">c</xref></td><td>1.0 (1.0–2.0)</td><td>1.0 (1.0–1.0)</td><td>1.0 (1.0–2.0)</td></tr><tr><td>Hypokalemia</td><td/><td/><td/></tr><tr><td> Participants, n/N (%)</td><td>19/69 (28)</td><td>21/68 (31)</td><td>40/137 (29)</td></tr><tr><td> OR (95% CI)<xref rid="tbl5fnd" ref-type="table-fn">d</xref></td><td/><td>1.23 (0.57–2.68)</td><td/></tr><tr><td> <italic>P</italic> value<xref rid="tbl5fnb" ref-type="table-fn">b</xref></td><td/><td>0.5904</td><td/></tr><tr><td> No. of events, median (IQR)<xref rid="tbl5fnc" ref-type="table-fn">c</xref></td><td>1.0 (1.0–2.0)</td><td>1.0 (1.0–2.0)</td><td>1.0 (1.0–2.0)</td></tr><tr><td><bold>Non–anion gap acidosis</bold></td><td/><td/><td/></tr><tr><td> Participants, n/N (%)</td><td>44/64 (69)</td><td>12/63 (19)</td><td>56/127 (44)</td></tr><tr><td> OR (95% CI)<xref rid="tbl5fna" ref-type="table-fn">a</xref></td><td/><td>0.09 (0.04–0.22)</td><td/></tr><tr><td> <italic>P</italic> value<xref rid="tbl5fnb" ref-type="table-fn">b</xref></td><td/><td>&lt;0.0001</td><td/></tr><tr><td> No. of events, median (IQR)<xref rid="tbl5fnc" ref-type="table-fn">c</xref></td><td>1.0 (1.0–2.0)</td><td>1.5 (1.0–2.0)</td><td>1.0 (1.0–2.0)</td></tr><tr><td><bold>Hypomagnesemia</bold></td><td/><td/><td/></tr><tr><td> Participants, n/N (%)</td><td>31/69 (45)</td><td>10/67 (15)</td><td>41/136 (30)</td></tr><tr><td> OR (95% CI)<xref rid="tbl5fne" ref-type="table-fn">e</xref></td><td/><td>0.21 (0.08–0.50)</td><td/></tr><tr><td> <italic>P</italic> value<xref rid="tbl5fnf" ref-type="table-fn">f</xref></td><td/><td>0.0001</td><td/></tr><tr><td> No. of events, median (IQR)<xref rid="tbl5fnc" ref-type="table-fn">c</xref></td><td>1.0 (1.0–2.0)</td><td>1.0 (1.0–1.0)</td><td>1.0 (1.0–2.0)</td></tr><tr><td><bold>Hyperchloremia</bold></td><td/><td/><td/></tr><tr><td> Participants, n/N (%)</td><td>59/69 (86)</td><td>36/68 (53)</td><td>95/137 (69)</td></tr><tr><td> OR (95% CI)<xref rid="tbl5fna" ref-type="table-fn">a</xref></td><td/><td>0.17 (0.07–0.40)</td><td/></tr><tr><td> <italic>P</italic> value<xref rid="tbl5fnb" ref-type="table-fn">b</xref></td><td/><td>&lt;0.0001</td><td/></tr><tr><td> No. of events, median (IQR)<xref rid="tbl5fnc" ref-type="table-fn">c</xref></td><td>1.0 (1.0–2.0)</td><td>1.0 (1.0–1.0)</td><td>1.0 (1.0–2.0)</td></tr><tr><td colspan="4"><bold>Excessive rate of reduction in plasma sodium concentration</bold></td></tr><tr><td> Participants, n/N (%)</td><td>2/69 (3)</td><td>1/68 (1)</td><td>3/137 (2)</td></tr><tr><td> OR (95% CI)<xref rid="tbl5fng" ref-type="table-fn">g</xref></td><td/><td>0.51 (0.01–9.84)</td><td/></tr><tr><td> <italic>P</italic> value<xref rid="tbl5fnf" ref-type="table-fn">f</xref></td><td/><td>1.0000</td><td/></tr><tr><td> No. of events, median (IQR)<xref rid="tbl5fnc" ref-type="table-fn">c</xref></td><td>1.0 (1.0–1.0)</td><td>1.0 (1.0–1.0)</td><td>1.0 (1.0–1.0)</td></tr><tr><td colspan="4"><bold>Excessive magnitude of reduction in plasma sodium concentration</bold></td></tr><tr><td> Participants, n/N (%)</td><td>5/68 (7)</td><td>0/68 (0)</td><td>5/136 (4)</td></tr><tr><td> OR (95% CI)<xref rid="tbl5fnh" ref-type="table-fn">h</xref></td><td/><td/><td/></tr><tr><td> <italic>P</italic> value<xref rid="tbl5fni" ref-type="table-fn">i</xref></td><td/><td/><td/></tr><tr><td> No. of events, median (IQR)<xref rid="tbl5fnc" ref-type="table-fn">c</xref></td><td>1.0 (1.0–1.0)</td><td/><td>1.0 (1.0–1.0)</td></tr></tbody></table><table-wrap-foot><fn><p>CI, confidence interval; IQR, interquartile range; OR, odds ratio.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl5fna"><label>a</label><p id="ntpara0040">Mixed logistic regression model adjusted for site, participant weight pretransplant, and donor type.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl5fnb"><label>b</label><p id="ntpara0045"><italic>P</italic> value from the likelihood ratio test when including and excluding the treatment term from the model.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl5fnc"><label>c</label><p id="ntpara0050">Per participant with at least 1 event.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl5fnd"><label>d</label><p id="ntpara0055">Mixed logistic regression model adjusted for site and participant weight pretransplant.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl5fne"><label>e</label><p id="ntpara0060">Exact logistic regression model adjusted for participant weight pretransplant and donor type.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl5fnf"><label>f</label><p id="ntpara0065"><italic>P</italic> value from the conditional exact score test when including and excluding the treatment term from the model.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl5fng"><label>g</label><p id="ntpara0070">Exact logistic regression model adjusted for participant weight pretransplant.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl5fnh"><label>h</label><p id="ntpara0075">No regression model could be fitted.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl5fni"><label>i</label><p id="ntpara0080">No regression model could be fitted.</p></fn></table-wrap-foot></table-wrap></p>
              <p id="p0135">Hypomagnesemia was less frequent in the Plasma-Lyte than standard fluid group (10/67 [15%] vs. 31/69 [45%] participants; OR, 0.21; 95% CI, 0.08–0.50; <italic>P</italic> = 0.0001; <xref rid="tbl5" ref-type="table">Table 5</xref> and <xref rid="fig2" ref-type="fig">Figure 2</xref>). Hypernatremia was more frequent with Plasma-Lyte, 17 of 68 (25%) compared with 8 of 69 (12%) in the standard fluid group (OR, 3.5; 95% CI, 1.1–10.8; <italic>P</italic> = 0.022; <xref rid="tbl5" ref-type="table">Table 5</xref> and <xref rid="fig2" ref-type="fig">Figure 2</xref>). There were no differences between groups for hyperkalemia, hypokalemia, and excessive rate and excessive magnitude of reduction in plasma sodium concentration (<xref rid="tbl5" ref-type="table">Table 5</xref> and <xref rid="fig2" ref-type="fig">Figures 2</xref> and <xref rid="fig3" ref-type="fig">3</xref>). When blood gas results were considered as a prespecified sensitivity, differences observed between the 2 treatment groups were comparable to those seen in plasma alone (<xref rid="appsec1" ref-type="sec">Supplementary Table S6</xref>).</p>
              <p id="p0140">The mean number of changes of fluid composition was 2.6 in the Plasma-Lyte group and 4.6 in the standard fluid group. When adjusted for donor type, pretransplant weight, site, and hours at risk of event, there was a significant difference in the number of changes between the 2 treatment groups, with a rate ratio of 0.52 (95% CI, 0.40–0.67; <italic>P</italic> &lt; 0.0001).</p>
              <p id="p0145">The median length of stay was 11 days in both treatment groups. No significant difference in the hazards of discharge between Plasma-Lyte and standard care groups was found (hazard ratio, 1.32; 95% CI, 0.93–1.86; <italic>P</italic> = 0.12; <xref rid="appsec1" ref-type="sec">Supplementary Table S7</xref>). The mean degree of fluid overload was 7.8% (SD, 7.8%) in the standard fluids group, and 7.7% (SD, 7.4%) with Plasma-Lyte-148 (<xref rid="appsec1" ref-type="sec">Supplementary Table S8</xref>).</p>
              <p id="p0150">Transplant function measured by estimated glomerular filtration rate on days 1, 3, and 7 post-transplant was similar between groups (<xref rid="appsec1" ref-type="sec">Supplementary Table S9</xref>; mean ratio, 1.11; 95% CI, 0.90–1.36; <italic>P</italic> = 0.34). Maximum and minimum systolic blood pressure percentiles were also similar between groups (<xref rid="appsec1" ref-type="sec">Supplementary Table S10</xref>). Hyperglycemia was not assessed because of a high rate of data missingness (30%).</p>
              <p id="p0155">A total of 13 serious adverse events were reported in 6 (9%) of 69 participants randomized to Plasma-Lyte and 5 (7%) of 69 randomized to standard fluids (<xref rid="appsec1" ref-type="sec">Supplementary Table S11</xref>). Prespecified safety outcomes of acute severe hyponatremia (reduction of &gt;10 mmol/L from pretransplant level or rate of reduction &gt;1 mmol/L per hour averaged over 6 hours on laboratory or blood gas samples) or severe hyperkalemia (&gt;6.5 mmol/L on laboratory or blood gas samples) were identified in 15 (22%) participants in the Plasma-Lyte group and 24 (35%) in the standard care group. Three kidney transplants failed in the first 90 days in the standard fluids group, and none failed in the Plasma-Lyte group. One participant in the Plasma-Lyte group died from an unrelated surgical complication.</p>
            </sec>
            <sec id="sec3">
              <title>Discussion</title>
              <p id="p0160">The present trial shows that for children receiving kidney transplants, perioperative administration of Plasma-Lyte-148 fluid did not reduce the incidence of hyponatremia compared with standard fluids. Standard fluids were changed more frequently than Plasma-Lyte-148, and they had higher rates of metabolic acidosis, hyperchloremia, and hypomagnesemia.</p>
              <p id="p0165">The equivalence of hyponatremia with use of both isotonic and predominantly hypotonic standard fluids in children receiving kidney transplants contrasts existing data from other clinical settings.<xref rid="bib9" ref-type="bibr">9</xref>, <xref rid="bib10" ref-type="bibr">10</xref>, <xref rid="bib11" ref-type="bibr">11</xref>, <xref rid="bib12" ref-type="bibr">12</xref>, <xref rid="bib13" ref-type="bibr">13</xref> This may relate to unique aspects of pediatric kidney transplant practice. The volume of fluids administered to participants exceeded 3 times usual maintenance amounts. Compounding this, the postoperative antidiuretic response limits water excretion. Clinically significant fluid overload was observed in most participants, with a mean increase in weight of 7.7% after transplant. Water overload may therefore underlie the markedly higher incidence of hyponatremia in the present study compared with the general pediatric population, and the lack of a difference with isotonic fluid. It is also possible that the trial lacked sufficient power to detect a difference in hyponatremia. The sample size was based on a systematic review comparing 0.9% sodium chloride with hypotonic fluid, and it did not include studies conducted in pediatric transplant recipients.<xref rid="bib9" ref-type="bibr"><sup>9</sup></xref> The tonicity of Plasma-Lyte-148 is lower than 0.9% sodium chloride, and the control group in our study received a combination of fluids. These factors may have diluted a difference in hyponatremia. Nevertheless, this trial does reduce uncertainty about the effect size with the first randomized data in this population.</p>
              <p id="p0170">Hypernatremia was more frequent with Plasma-Lyte-148 than standard fluids in the present study, consistent with data in children with acute illness.<xref rid="bib22" ref-type="bibr"><sup>22</sup></xref> The clinical relevance of this is unknown; no related adverse events were reported.</p>
              <p id="p0175">The type of i.v. fluid administered was changed a mean of 4.6 times in 72 hours in the standard fluid group, and 2.6 times in the Plasma-Lyte group. Frequent blood tests and changes to fluids consume significant health care resources. The present trial did not include a health economic analysis; however, the potential cost benefit of reducing fluid changes and blood tests with use of Plasma-Lyte-148 could be evaluated in future research.</p>
              <p id="p0180">The present trial found less hyperchloremia and less metabolic acidosis with Plasma-Lyte-148 than standard fluids. This finding is consistent with a systematic review and subsequent randomized trial in adult kidney transplant recipients, and a randomized trial in children on intensive care.<xref rid="bib23" ref-type="bibr">23</xref>, <xref rid="bib24" ref-type="bibr">24</xref>, <xref rid="bib25" ref-type="bibr">25</xref> A recent randomized trial in deceased donor kidney transplant recipients found that Plasma-Lyte-148 reduced the incidence of delayed graft function compared with 0.9% sodium chloride; our study did not assess this outcome in children.<xref rid="bib26" ref-type="bibr"><sup>26</sup></xref> We observed no difference in transplant kidney function, graft survival, or patient survival between the Plasma-Lyte-148 and standard fluid groups, although the study was not powered for these outcomes. This concurs with findings from a recent clinical trial in critically ill adult patients that compared acute kidney injury and patient survival with Plasma-Lyte-148 with 0.9% sodium chloride fluid, and contrasts with previous data suggesting a benefit to kidney and survival outcomes from balanced fluid.<xref rid="bib17" ref-type="bibr"><sup>17</sup></xref><sup>,</sup><xref rid="bib18" ref-type="bibr"><sup>18</sup></xref></p>
              <p id="p0185">A perceived risk of hyperkalemia from the potassium content of Plasma-Lyte concerned some pediatric nephrologists; however, the incidence of hyperkalemia was no greater with Plasma-Lyte-148 than predominantly potassium-free standard fluids in the present trial. This is consistent with data in adult kidney transplant recipients.<xref rid="bib23" ref-type="bibr"><sup>23</sup></xref><sup>,</sup><xref rid="bib24" ref-type="bibr"><sup>24</sup></xref><sup>,</sup><xref rid="bib27" ref-type="bibr"><sup>27</sup></xref> Previous concerns about an increased risk of hyperkalemia with use of Plasma-Lyte-148 appear not to be justified.</p>
              <p id="p0190">Hypomagnesemia is an independent risk factor for new-onset diabetes after transplant in adult kidney recipients; however, the association in children has not been established.<xref rid="bib28" ref-type="bibr"><sup>28</sup></xref><sup>,</sup><xref rid="bib29" ref-type="bibr"><sup>29</sup></xref> In the present study, fewer participants experienced hypomagnesemia with Plasma-Lyte-148 than standard fluids. Insufficient blood glucose data were available to examine the secondary outcome of post-transplant hyperglycemia in the present trial; the possibility of a benefit from Plasma-Lyte-148 on post-transplant diabetes mellitus could be evaluated in future research.</p>
              <p id="p0195">Our study had several strengths: it recruited a high proportion of eligible children from most of UK children’s kidney transplant centers. Of the 179 pediatric kidney transplants performed during the period each site was open, 138 (77%) were randomized in the trial, with a diverse range of heritage backgrounds. We used a pragmatic approach with intervention and comparator treatments that reflects care as it is delivered in real-world clinical practice. Limitations included the open-label design; blinding was not considered feasible, which may have impacted the treatment effect. Plasma sodium levels were a focus of clinicians’ postoperative management, as reflected by multiple changes to the type of i.v. fluids used in the standard fluids group. Furthermore, standardization of fluids administered in the control group was not feasible because of variation in the fluid regimens used between different clinicians and sites, and the established practice of changing fluid in response to frequent blood test monitoring. Postoperative urine output data were not collected. Per-protocol and subgroup analyses to account for different types of fluid used in both the intervention and control groups confirmed the primary results, although the study was not powered for these analyses.</p>
              <p id="p0200">The primary result of our study was unexpected because it contrasts with evidence in other populations. Postoperative hyponatremia is common in children receiving transplants, and the lack of improvement with balanced isotonic fluid warrants further evaluation; whether lower volumes of i.v. fluid would reduce the incidence of hyponatremia in this population is unknown.</p>
              <p id="p0205">In conclusion, Plasma-Lyte-148 fluid did not change the incidence of acute hyponatremia in children receiving kidney transplants compared with standard i.v. fluids. Fewer fluid prescription changes were made with Plasma-Lyte-148, and hyperchloremia and acidosis were less common.</p>
            </sec>
            <sec id="sec4">
              <title>Disclosure</title>
              <p id="p0210">All the authors declared no competing interests.</p>
            </sec>
            <sec id="sec5">
              <title>Data Statement</title>
              <p id="p0215">Data requests should be submitted to the corresponding author (Plasma-Lyte Usage and Assessment of Kidney Transplant Outcomes in Children [PLUTO] chief investigator WNH: <email>wesley.hayes@gosh.nhs.uk</email>) or the PLUTO Trial Manager (<email>PLUTO@nhsbt.nhs.uk</email>). A full data sharing request form will be required, which will be reviewed by the sponsor and/or the relevant National Health Service (NHS) Blood and Transplant research group, depending on the scope. Full anonymized data sets will be available no later than 18 months after the last participant was recruited. The study protocol has previously been published (<ext-link ext-link-type="doi" xlink:href="10.1136/bmjopen-2021-055595" id="intref0020">https://doi.org/10.1136/bmjopen-2021-055595</ext-link>), and the statistical analysis plan is included in the supplementary material. The types of analyses and mechanisms are to be agreed as part of the data request before data sharing, and a contract is mandatory before data are shared with a third party.</p>
            </sec>
          </body>
          <back>
            <ref-list id="cebib0010">
              <title>References</title>
              <ref id="bib1">
                <label>1</label>
                <element-citation publication-type="journal" id="sref1">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Roach</surname>
                      <given-names>J.P.</given-names>
                    </name>
                    <name>
                      <surname>Bock</surname>
                      <given-names>M.E.</given-names>
                    </name>
                    <name>
                      <surname>Goebel</surname>
                      <given-names>J.</given-names>
                    </name>
                  </person-group>
                  <article-title>Pediatric kidney transplantation</article-title>
                  <source>Semin Pediatr Surg</source>
                  <volume>26</volume>
                  <year>2017</year>
                  <fpage>233</fpage>
                  <lpage>240</lpage>
                  <pub-id pub-id-type="pmid">28964479</pub-id>
                </element-citation>
              </ref>
              <ref id="bib2">
                <label>2</label>
                <element-citation publication-type="journal" id="sref2">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hayes</surname>
                      <given-names>W.</given-names>
                    </name>
                    <name>
                      <surname>Longley</surname>
                      <given-names>C.</given-names>
                    </name>
                    <name>
                      <surname>Scanlon</surname>
                      <given-names>N.</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Plasma electrolyte imbalance in pediatric kidney transplant recipients</article-title>
                  <source>Pediatr Transplant</source>
                  <volume>23</volume>
                  <year>2019</year>
                  <object-id pub-id-type="publisher-id">e13411</object-id>
                </element-citation>
              </ref>
              <ref id="bib3">
                <label>3</label>
                <element-citation publication-type="journal" id="sref3">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Cansick</surname>
                      <given-names>J.</given-names>
                    </name>
                    <name>
                      <surname>Rees</surname>
                      <given-names>L.</given-names>
                    </name>
                    <name>
                      <surname>Koffman</surname>
                      <given-names>G.</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>A fatal case of cerebral oedema with hyponatraemia and massive polyuria after renal transplantation</article-title>
                  <source>Pediatr Nephrol</source>
                  <volume>24</volume>
                  <year>2009</year>
                  <fpage>1231</fpage>
                  <lpage>1234</lpage>
                  <pub-id pub-id-type="pmid">19153773</pub-id>
                </element-citation>
              </ref>
              <ref id="bib4">
                <label>4</label>
                <element-citation publication-type="journal" id="sref4">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Drake</surname>
                      <given-names>K.</given-names>
                    </name>
                    <name>
                      <surname>Nehus</surname>
                      <given-names>E.</given-names>
                    </name>
                    <name>
                      <surname>Goebel</surname>
                      <given-names>J.</given-names>
                    </name>
                  </person-group>
                  <article-title>Hyponatremia, hypo-osmolality, and seizures in children early post-kidney transplant</article-title>
                  <source>Pediatr Transplant</source>
                  <volume>19</volume>
                  <year>2015</year>
                  <fpage>698</fpage>
                  <lpage>703</lpage>
                  <pub-id pub-id-type="pmid">26299753</pub-id>
                </element-citation>
              </ref>
              <ref id="bib5">
                <label>5</label>
                <element-citation publication-type="journal" id="sref5">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Arieff</surname>
                      <given-names>A.I.</given-names>
                    </name>
                    <name>
                      <surname>Ayus</surname>
                      <given-names>J.C.</given-names>
                    </name>
                    <name>
                      <surname>Fraser</surname>
                      <given-names>C.L.</given-names>
                    </name>
                  </person-group>
                  <article-title>Hyponatraemia and death or permanent brain damage in healthy children</article-title>
                  <source>BMJ</source>
                  <volume>304</volume>
                  <year>1992</year>
                  <fpage>1218</fpage>
                  <lpage>1222</lpage>
                  <pub-id pub-id-type="pmid">1515791</pub-id>
                </element-citation>
              </ref>
              <ref id="bib6">
                <label>6</label>
                <element-citation publication-type="journal" id="sref6">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ayus</surname>
                      <given-names>J.C.</given-names>
                    </name>
                    <name>
                      <surname>Achinger</surname>
                      <given-names>S.G.</given-names>
                    </name>
                    <name>
                      <surname>Arieff</surname>
                      <given-names>A.</given-names>
                    </name>
                  </person-group>
                  <article-title>Brain cell volume regulation in hyponatremia: role of sex, age, vasopressin, and hypoxia</article-title>
                  <source>Am J Physiol Renal Physiol</source>
                  <volume>295</volume>
                  <year>2008</year>
                  <fpage>F619</fpage>
                  <lpage>F624</lpage>
                  <pub-id pub-id-type="pmid">18448591</pub-id>
                </element-citation>
              </ref>
              <ref id="bib7">
                <label>7</label>
                <element-citation publication-type="journal" id="sref7">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Gankam Kengne</surname>
                      <given-names>F.</given-names>
                    </name>
                    <name>
                      <surname>Decaux</surname>
                      <given-names>G.</given-names>
                    </name>
                  </person-group>
                  <article-title>Hyponatremia and the brain</article-title>
                  <source>Kidney Int Rep</source>
                  <volume>3</volume>
                  <year>2018</year>
                  <fpage>24</fpage>
                  <lpage>35</lpage>
                  <pub-id pub-id-type="pmid">29340311</pub-id>
                </element-citation>
              </ref>
              <ref id="bib8">
                <label>8</label>
                <element-citation publication-type="journal" id="sref8">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Giuliani</surname>
                      <given-names>C.</given-names>
                    </name>
                    <name>
                      <surname>Peri</surname>
                      <given-names>A.</given-names>
                    </name>
                  </person-group>
                  <article-title>Effects of hyponatremia on the brain</article-title>
                  <source>J Clin Med</source>
                  <volume>3</volume>
                  <year>2014</year>
                  <fpage>1163</fpage>
                  <lpage>1177</lpage>
                  <pub-id pub-id-type="pmid">26237597</pub-id>
                </element-citation>
              </ref>
              <ref id="bib9">
                <label>9</label>
                <element-citation publication-type="journal" id="sref9">
                  <person-group person-group-type="author">
                    <name>
                      <surname>McNab</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Ware</surname>
                      <given-names>R.S.</given-names>
                    </name>
                    <name>
                      <surname>Neville</surname>
                      <given-names>K.A.</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Isotonic versus hypotonic solutions for maintenance intravenous fluid administration in children</article-title>
                  <source>Cochrane Database Syst Rev</source>
                  <volume>12</volume>
                  <year>2014</year>
                  <fpage>CD009457</fpage>
                </element-citation>
              </ref>
              <ref id="bib10">
                <label>10</label>
                <element-citation publication-type="journal" id="sref10">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Foster</surname>
                      <given-names>B.A.</given-names>
                    </name>
                    <name>
                      <surname>Tom</surname>
                      <given-names>D.</given-names>
                    </name>
                    <name>
                      <surname>Hill</surname>
                      <given-names>V.</given-names>
                    </name>
                  </person-group>
                  <article-title>Hypotonic versus isotonic fluids in hospitalized children: a systematic review and meta-analysis</article-title>
                  <source>J Pediatr</source>
                  <volume>165</volume>
                  <year>2014</year>
                  <fpage>163</fpage>
                  <lpage>169.e2</lpage>
                  <pub-id pub-id-type="pmid">24582105</pub-id>
                </element-citation>
              </ref>
              <ref id="bib11">
                <label>11</label>
                <element-citation publication-type="journal" id="sref11">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Wang</surname>
                      <given-names>J.</given-names>
                    </name>
                    <name>
                      <surname>Xu</surname>
                      <given-names>E.</given-names>
                    </name>
                    <name>
                      <surname>Xiao</surname>
                      <given-names>Y.</given-names>
                    </name>
                  </person-group>
                  <article-title>Isotonic versus hypotonic maintenance IV fluids in hospitalized children: a meta-analysis</article-title>
                  <source>Pediatrics</source>
                  <volume>133</volume>
                  <year>2014</year>
                  <fpage>105</fpage>
                  <lpage>113</lpage>
                  <pub-id pub-id-type="pmid">24379232</pub-id>
                </element-citation>
              </ref>
              <ref id="bib12">
                <label>12</label>
                <element-citation publication-type="journal" id="sref12">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Choong</surname>
                      <given-names>K.</given-names>
                    </name>
                    <name>
                      <surname>Kho</surname>
                      <given-names>M.E.</given-names>
                    </name>
                    <name>
                      <surname>Menon</surname>
                      <given-names>K.</given-names>
                    </name>
                    <name>
                      <surname>Bohn</surname>
                      <given-names>D.</given-names>
                    </name>
                  </person-group>
                  <article-title>Hypotonic versus isotonic saline in hospitalised children: a systematic review</article-title>
                  <source>Arch Dis Child</source>
                  <volume>91</volume>
                  <year>2006</year>
                  <fpage>828</fpage>
                  <lpage>835</lpage>
                  <pub-id pub-id-type="pmid">16754657</pub-id>
                </element-citation>
              </ref>
              <ref id="bib13">
                <label>13</label>
                <element-citation publication-type="journal" id="sref13">
                  <person-group person-group-type="author">
                    <name>
                      <surname>McNab</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Duke</surname>
                      <given-names>T.</given-names>
                    </name>
                    <name>
                      <surname>South</surname>
                      <given-names>M.</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>140 mmol/L of sodium versus 77 mmol/L of sodium in maintenance intravenous fluid therapy for children in hospital (PIMS): a randomised controlled double-blind trial</article-title>
                  <source>Lancet</source>
                  <volume>385</volume>
                  <year>2015</year>
                  <fpage>1190</fpage>
                  <lpage>1197</lpage>
                  <pub-id pub-id-type="pmid">25472864</pub-id>
                </element-citation>
              </ref>
              <ref id="bib14">
                <label>14</label>
                <element-citation publication-type="journal" id="sref14">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ratnjeet</surname>
                      <given-names>K.</given-names>
                    </name>
                    <name>
                      <surname>Pallavi</surname>
                      <given-names>P.</given-names>
                    </name>
                    <name>
                      <surname>Jhamb</surname>
                      <given-names>U.</given-names>
                    </name>
                    <name>
                      <surname>Saxena</surname>
                      <given-names>R.</given-names>
                    </name>
                  </person-group>
                  <article-title>45% Versus 0.9% saline in 5% dextrose as maintenance fluids in children admitted with acute illness: a randomized control trial</article-title>
                  <source>Pediatr Emerg Care</source>
                  <volume>38</volume>
                  <year>2022</year>
                  <fpage>436</fpage>
                  <lpage>441</lpage>
                  <comment>0</comment>
                  <pub-id pub-id-type="pmid">36040464</pub-id>
                </element-citation>
              </ref>
              <ref id="bib15">
                <label>15</label>
                <element-citation publication-type="other" id="sref15">
                  <person-group person-group-type="author">
                    <collab>National Institute for Health and Care Excellence (NICE)</collab>
                  </person-group>
                  <article-title>Intravenous fluid therapy in children and young people in hospital, NICE guideline [NG29]</article-title>
                  <comment>Published December 9, 2015. Last updated June 11, 2020</comment>
                  <ext-link ext-link-type="uri" xlink:href="https://www.nice.org.uk/guidance/ng29" id="intref007735">https://www.nice.org.uk/guidance/ng29</ext-link>
                </element-citation>
              </ref>
              <ref id="bib16">
                <label>16</label>
                <element-citation publication-type="other" id="sref30896">
                  <person-group person-group-type="author">
                    <collab>Electronic medicines compendium (emc)</collab>
                  </person-group>
                  <article-title>Plasma-Lyte 148 (pH 7.4) solution for infusion. Summary of Product Characteristics (SmPC)</article-title>
                  <comment>Last updated emc December 12, 2018</comment>
                  <ext-link ext-link-type="uri" xlink:href="http://medicines.org.uk" id="intref003574sw">medicines.org.uk</ext-link>
                </element-citation>
              </ref>
              <ref id="bib17">
                <label>17</label>
                <element-citation publication-type="journal" id="sref17">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Semler</surname>
                      <given-names>M.W.</given-names>
                    </name>
                    <name>
                      <surname>Self</surname>
                      <given-names>W.H.</given-names>
                    </name>
                    <name>
                      <surname>Wanderer</surname>
                      <given-names>J.P.</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Balanced crystalloids versus saline in critically ill adults</article-title>
                  <source>N Engl J Med</source>
                  <volume>378</volume>
                  <year>2018</year>
                  <fpage>829</fpage>
                  <lpage>839</lpage>
                  <pub-id pub-id-type="pmid">29485925</pub-id>
                </element-citation>
              </ref>
              <ref id="bib18">
                <label>18</label>
                <element-citation publication-type="journal" id="sref18">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Finfer</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Micallef</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Hammond</surname>
                      <given-names>N.</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Balanced multielectrolyte solution versus saline in critically ill adults</article-title>
                  <source>N Engl J Med</source>
                  <volume>386</volume>
                  <year>2022</year>
                  <fpage>815</fpage>
                  <lpage>826</lpage>
                  <pub-id pub-id-type="pmid">35041780</pub-id>
                </element-citation>
              </ref>
              <ref id="bib19">
                <label>19</label>
                <element-citation publication-type="journal" id="sref19">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Self</surname>
                      <given-names>W.H.</given-names>
                    </name>
                    <name>
                      <surname>Semler</surname>
                      <given-names>M.W.</given-names>
                    </name>
                    <name>
                      <surname>Wanderer</surname>
                      <given-names>J.P.</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Balanced crystalloids versus saline in noncritically ill adults</article-title>
                  <source>N Engl J Med</source>
                  <volume>378</volume>
                  <year>2018</year>
                  <fpage>819</fpage>
                  <lpage>828</lpage>
                  <pub-id pub-id-type="pmid">29485926</pub-id>
                </element-citation>
              </ref>
              <ref id="bib20">
                <label>20</label>
                <element-citation publication-type="journal" id="sref20">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Weiss</surname>
                      <given-names>S.L.</given-names>
                    </name>
                    <name>
                      <surname>Balamuth</surname>
                      <given-names>F.</given-names>
                    </name>
                    <name>
                      <surname>Long</surname>
                      <given-names>E.</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>PRagMatic Pediatric Trial of Balanced vs nOrmaL Saline FlUid in Sepsis: study protocol for the PRoMPT BOLUS randomized interventional trial</article-title>
                  <source>Trials</source>
                  <volume>22</volume>
                  <year>2021</year>
                  <fpage>776</fpage>
                  <pub-id pub-id-type="pmid">34742327</pub-id>
                </element-citation>
              </ref>
              <ref id="bib21">
                <label>21</label>
                <element-citation publication-type="journal" id="sref21">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hayes</surname>
                      <given-names>W.</given-names>
                    </name>
                    <name>
                      <surname>Laing</surname>
                      <given-names>E.</given-names>
                    </name>
                    <name>
                      <surname>Foley</surname>
                      <given-names>C.</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Multicentre randomised controlled trial: protocol for Plasma-Lyte Usage and Assessment of Kidney Transplant Outcomes in Children (PLUTO)</article-title>
                  <source>BMJ Open</source>
                  <volume>12</volume>
                  <year>2022</year>
                  <object-id pub-id-type="publisher-id">e055595</object-id>
                </element-citation>
              </ref>
              <ref id="bib22">
                <label>22</label>
                <element-citation publication-type="journal" id="sref22">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Lehtiranta</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Honkila</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>Kallio</surname>
                      <given-names>M.</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Risk of electrolyte disorders in acutely ill children receiving commercially available plasmalike isotonic fluids: a randomized clinical trial</article-title>
                  <source>JAMA Pediatr</source>
                  <volume>175</volume>
                  <year>2021</year>
                  <fpage>28</fpage>
                  <lpage>35</lpage>
                  <pub-id pub-id-type="pmid">33104176</pub-id>
                </element-citation>
              </ref>
              <ref id="bib23">
                <label>23</label>
                <element-citation publication-type="journal" id="sref23">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Wan</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Roberts</surname>
                      <given-names>M.A.</given-names>
                    </name>
                    <name>
                      <surname>Mount</surname>
                      <given-names>P.</given-names>
                    </name>
                  </person-group>
                  <article-title>Normal saline versus lower-chloride solutions for kidney transplantation</article-title>
                  <source>Cochrane Database Syst Rev</source>
                  <volume>8</volume>
                  <year>2016</year>
                  <fpage>CD010741</fpage>
                </element-citation>
              </ref>
              <ref id="bib24">
                <label>24</label>
                <element-citation publication-type="journal" id="sref24">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Weinberg</surname>
                      <given-names>L.</given-names>
                    </name>
                    <name>
                      <surname>Harris</surname>
                      <given-names>L.</given-names>
                    </name>
                    <name>
                      <surname>Bellomo</surname>
                      <given-names>R.</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Effects of intraoperative and early postoperative normal saline or Plasma-Lyte 148(R) on hyperkalaemia in deceased donor renal transplantation: a double-blind randomized trial</article-title>
                  <source>Br J Anaesth</source>
                  <volume>119</volume>
                  <year>2017</year>
                  <fpage>606</fpage>
                  <lpage>615</lpage>
                  <pub-id pub-id-type="pmid">29121282</pub-id>
                </element-citation>
              </ref>
              <ref id="bib25">
                <label>25</label>
                <element-citation publication-type="journal" id="sref25">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Raman</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Gibbons</surname>
                      <given-names>K.S.</given-names>
                    </name>
                    <name>
                      <surname>Mattke</surname>
                      <given-names>A.</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Effect of saline vs gluconate/acetate-buffered solution vs lactate-buffered solution on serum chloride among children in the pediatric intensive care unit: the SPLYT-P randomized clinical trial</article-title>
                  <source>JAMA Pediatr</source>
                  <volume>177</volume>
                  <year>2023</year>
                  <fpage>122</fpage>
                  <lpage>131</lpage>
                  <pub-id pub-id-type="pmid">36534387</pub-id>
                </element-citation>
              </ref>
              <ref id="bib26">
                <label>26</label>
                <element-citation publication-type="journal" id="sref26">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Collins</surname>
                      <given-names>M.G.</given-names>
                    </name>
                    <name>
                      <surname>Fahim</surname>
                      <given-names>M.A.</given-names>
                    </name>
                    <name>
                      <surname>Pascoe</surname>
                      <given-names>E.M.</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Balanced crystalloid solution versus saline in deceased donor kidney transplantation (BEST-Fluids): a pragmatic, double-blind, randomised, controlled trial</article-title>
                  <source>Lancet</source>
                  <volume>402</volume>
                  <year>2023</year>
                  <fpage>105</fpage>
                  <lpage>117</lpage>
                  <pub-id pub-id-type="pmid">37343576</pub-id>
                </element-citation>
              </ref>
              <ref id="bib27">
                <label>27</label>
                <element-citation publication-type="journal" id="sref27">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Adwaney</surname>
                      <given-names>A.</given-names>
                    </name>
                    <name>
                      <surname>Randall</surname>
                      <given-names>D.W.</given-names>
                    </name>
                    <name>
                      <surname>Blunden</surname>
                      <given-names>M.J.</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Perioperative Plasma-Lyte use reduces the incidence of renal replacement therapy and hyperkalaemia following renal transplantation when compared with 0.9% saline: a retrospective cohort study</article-title>
                  <source>Clin Kidney J</source>
                  <volume>10</volume>
                  <year>2017</year>
                  <fpage>838</fpage>
                  <lpage>844</lpage>
                  <pub-id pub-id-type="pmid">29225814</pub-id>
                </element-citation>
              </ref>
              <ref id="bib28">
                <label>28</label>
                <element-citation publication-type="journal" id="sref28">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Huang</surname>
                      <given-names>J.W.</given-names>
                    </name>
                    <name>
                      <surname>Famure</surname>
                      <given-names>O.</given-names>
                    </name>
                    <name>
                      <surname>Li</surname>
                      <given-names>Y.</given-names>
                    </name>
                    <name>
                      <surname>Kim</surname>
                      <given-names>S.J.</given-names>
                    </name>
                  </person-group>
                  <article-title>Hypomagnesemia and the risk of new-onset diabetes mellitus after kidney transplantation</article-title>
                  <source>J Am Soc Nephrol</source>
                  <volume>27</volume>
                  <year>2016</year>
                  <fpage>1793</fpage>
                  <lpage>1800</lpage>
                  <pub-id pub-id-type="pmid">26449610</pub-id>
                </element-citation>
              </ref>
              <ref id="bib29">
                <label>29</label>
                <element-citation publication-type="journal" id="sref29">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Chanchlani</surname>
                      <given-names>R.</given-names>
                    </name>
                    <name>
                      <surname>Joseph Kim</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Kim</surname>
                      <given-names>E.D.</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Incidence of hyperglycemia and diabetes and association with electrolyte abnormalities in pediatric solid organ transplant recipients</article-title>
                  <source>Nephrol Dial Transplant</source>
                  <volume>32</volume>
                  <year>2017</year>
                  <fpage>1579</fpage>
                  <lpage>1586</lpage>
                  <pub-id pub-id-type="pmid">29059403</pub-id>
                </element-citation>
              </ref>
            </ref-list>
            <sec id="appsec1" sec-type="supplementary-material">
              <title>Supplementary Material</title>
              <p id="p0250">
                <supplementary-material content-type="local-data" id="mmc1">
                  <caption>
                    <title>Supplementary File (Word)</title>
                  </caption>
                  <media xlink:href="mmc1.docx"/>
                </supplementary-material>
              </p>
              <p id="p0255">
                <bold>Supplementary protocol versions 1.0, 1.1, and 2.0 and summary of changes.</bold>
              </p>
              <p id="p0260">
                <bold>Supplementary statistical analysis plan, version 1.1.</bold>
              </p>
              <p id="p0265"><bold>Supplementary Table S1.</bold> Other outcome: medication and blood products.</p>
              <p id="p0270"><bold>Supplementary Table S2.</bold> Subgroup analysis: acute hyponatremia.</p>
              <p id="p0275"><bold>Supplementary Table S3.</bold> Sensitivity analysis: acute hyponatremia.</p>
              <p id="p0280"><bold>Supplementary Table S4.</bold> Secondary outcome: symptoms of acute hyponatremia.</p>
              <p id="p0285"><bold>Supplementary Table S5.</bold> Other outcome: investigation into acute hyponatremia and plasma sodium concentration.</p>
              <p id="p0290"><bold>Supplementary Table S6.</bold> Sensitivity analysis: other electrolyte abnormalities.</p>
              <p id="p0295"><bold>Supplementary Table S7.</bold> Secondary outcome: time to discharge.</p>
              <p id="p0300"><bold>Supplementary Table S8.</bold> Secondary outcomes: fluid overload and fluid prescription changes.</p>
              <p id="p0305"><bold>Supplementary Table S9.</bold> Secondary outcome: transplant kidney function.</p>
              <p id="p0310"><bold>Supplementary Table S10.</bold> Secondary outcome: systolic blood pressure.</p>
              <p id="p0315"><bold>Supplementary Table S11.</bold> Other outcome: serious adverse events and survival.</p>
              <p id="p0320">
                <bold>Supplementary Trial trial management group.</bold>
              </p>
              <p id="p0325">
                <bold>Supplementary independent trial steering committee.</bold>
              </p>
              <p id="p0330">
                <bold>Supplementary independent data monitoring ethics committee.</bold>
              </p>
              <p id="p0335">
                <bold>Supplemental statistical methods.</bold>
              </p>
            </sec>
            <ack id="ack0010">
              <title>Acknowledgments</title>
              <p id="p0220">This project was funded by the <funding-source id="gs100">National Institute for Health and Care Research (NIHR)</funding-source> under its Research for Patient Benefit Program (grant reference number NIHR200512).</p>
              <p id="p0225">The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care.</p>
              <p id="p0230">The study was sponsored by Great Ormond Street Hospital for Children National Health Service (NHS) Foundation Trust and supported by the Data Research Innovation and Virtual Environments Team at Great Ormond Street Hospital.</p>
              <p id="p0235">Our thanks to patient and parent representatives who have contributed to the design of this study, and to the NIHR Great Ormond Street Hospital Young Person's Advisory Group for research for codesigning patient information resources.</p>
              <p id="p0240">We are grateful to members of the trial oversight committees who supported delivery of the study: Karen Stevenson (NHS Greater Glasgow and Clyde), Christopher Watson and David Inwald (Cambridge University Hospitals NHS Foundation Trust), Kerri Barber (ICON plc), Simon Knight (Nuffield Department of Surgical Sciences, Centre for Evidence in Transplantation), Francesca Clemons and Renate Hodge (National Health Service Blood and Transplant Clinical Trials Unit), Mandy Wan and Rachel Hilton (Evelina Children’s Hospital), Mairead Convery (Belfast Health and Social Care Trust), Shivaram Hegde (University Hospital of Wales Cardiff), Henry Morgan and Philip Arnold (Alder Hey Children's NHS Foundation Trust), Shuman Haq (University Hospital Southampton NHS Foundation Trust), Helen Dalgleish and Angela Branson (Manchester University NHS Foundation Trust), Ilyas Ali (Great Ormond Street Hospital for Children NHS Foundation Trust), and Nicholas Prince (St George’s Hospital).</p>
              <sec id="sec6">
                <title>Author Contributions</title>
                <p id="p0245">WNH developed the idea for this study, drafted this manuscript, and had oversight of the study delivery with mentorship from MJP. WNH, EL, LSm, HT, and MJP applied for funding and developed the trial protocol. HH-S, SDM, NK, MC, JD, MS, MMa, MMu, NW, PY, WB, JW, and AS are coinvestigators and contributed to delivery of the trial. EL, FK, and JG are the trial managers, RS is the data manager, and RB, LSi, LSm, and HT are the trial statisticians at the National Health Service (NHS) Blood and Transplant Clinical Trials Unit, all of whom had direct access to the data, and verified the data and the statistical analyses. All authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.</p>
              </sec>
            </ack>
            <fn-group>
              <fn id="d35e1804">
                <p id="ntpara0011">
                  <ext-link ext-link-type="uri" xlink:href="https://www.kidney-international.org/article/S0085-2538(23)00799-8/fulltext" id="interref0011">see commentary on page 247</ext-link>
                </p>
              </fn>
              <fn id="appsec2" fn-type="supplementary-material">
                <p id="p0340">
                  <ext-link ext-link-type="doi" xlink:href="10.1016/j.kint.2023.09.032" id="intref0025">Supplementary File (Word)</ext-link>
                </p>
                <p id="p0345">
                  <bold>Supplementary protocol versions 1.0, 1.1, and 2.0 and summary of changes.</bold>
                </p>
                <p id="p0350">
                  <bold>Supplementary statistical analysis plan, version 1.1.</bold>
                </p>
                <p id="p0355"><bold>Supplementary Table S1.</bold> Other outcome: medication and blood products.</p>
                <p id="p0360"><bold>Supplementary Table S2.</bold> Subgroup analysis: acute hyponatremia.</p>
                <p id="p0365"><bold>Supplementary Table S3.</bold> Sensitivity analysis: acute hyponatremia.</p>
                <p id="p0370"><bold>Supplementary Table S4.</bold> Secondary outcome: symptoms of acute hyponatremia.</p>
                <p id="p0375"><bold>Supplementary Table S5.</bold> Other outcome: investigation into acute hyponatremia and plasma sodium concentration.</p>
                <p id="p0380"><bold>Supplementary Table S6.</bold> Sensitivity analysis: other electrolyte abnormalities.</p>
                <p id="p0385"><bold>Supplementary Table S7.</bold> Secondary outcome: time to discharge.</p>
                <p id="p0390"><bold>Supplementary Table S8.</bold> Secondary outcomes: fluid overload and fluid prescription changes.</p>
                <p id="p0395"><bold>Supplementary Table S9.</bold> Secondary outcome: transplant kidney function.</p>
                <p id="p0400"><bold>Supplementary Table S10.</bold> Secondary outcome: systolic blood pressure.</p>
                <p id="p0405"><bold>Supplementary Table S11.</bold> Other outcome: serious adverse events and survival.</p>
                <p id="p0410">
                  <bold>Supplementary Trial trial management group.</bold>
                </p>
                <p id="p0415">
                  <bold>Supplementary independent trial steering committee.</bold>
                </p>
                <p id="p0420">
                  <bold>Supplementary independent data monitoring ethics committee.</bold>
                </p>
                <p id="p0425">
                  <bold>Supplemental statistical methods.</bold>
                </p>
              </fn>
            </fn-group>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
